| 0.09 -0.001 (-1.32%) | 06-14 15:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.11 | 1-year : | 0.13 |
| Resists | First : | 0.1 | Second : | 0.11 |
| Pivot price | 0.08 |
|||
| Supports | First : | 0.08 | Second : | 0.07 |
| MAs | MA(5) : | 0.09 | MA(20) : | 0.09 |
| MA(100) : | 0.15 |
MA(250) : | 0.32 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.8 |
D(3) : | 63 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 1.17 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BCEL ] has closed below upper band by 49.0%. Bollinger Bands are 88.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 48 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.09 - 0.09 | 0.09 - 0.09 |
| Low: | 0.09 - 0.09 | 0.09 - 0.09 |
| Close: | 0.09 - 0.09 | 0.09 - 0.09 |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Wed, 17 Apr 2024
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCX - PR Newswire
Thu, 11 Jan 2024
Why Is Atreca (BCEL) Stock Up 85% Today? - InvestorPlace
Thu, 28 Dec 2023
Immunome to buy assets from California biotech company - The Business Journals
Tue, 26 Dec 2023
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome - GlobeNewswire
Thu, 12 Oct 2023
Mid-Peninsula project rode biotech's boom. Now it's showing how to survive the bust - The Business Journals
Mon, 14 Aug 2023
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 8.3 (%) |
| Shares Short | 273 (K) |
| Shares Short P.Month | 3,910 (K) |
| EPS | -2.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.3 % |
| Return on Equity (ttm) | -182.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -65 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|